RCKT — Rocket Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $770.93m
- $419.84m
- 40
- 26
- 19
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.66 | ||
| Price to Tang. Book | 1.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.1% | ||
| Return on Equity | -54.14% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 47.7 | 140.87 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Directors
- Roderick Wong CHM (43)
- Kinnari Patel PRE (42)
- Gaurav Shah CEO (46)
- Carlos Garciaparada CFO (56)
- Isabel Carmona CHO
- Martin Wilson SVP
- John Militello CAO (47)
- Jonathan Schwartz OTH (57)
- Elisabeth Bjork IND (59)
- Carsten Boess IND (54)
- Pedro Granadillo IND (74)
- Gotham Makker IND (47)
- David Southwell IND (60)
- Naveen Yalamanchi IND (44)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 7th, 1999
- Public Since
- February 18th, 2015
- No. of Shareholders
- 31
- No. of Employees
- 299
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 106,629,701
- Address
- 9 Cedarbrook Drive, CRANBURY, 08512
- Web
- https://www.rocketpharma.com/
- Phone
- +1 null6464409100
- Auditors
- EisnerAmper LLP
Upcoming Events for RCKT
Rocket Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Rocket Pharmaceuticals Inc Earnings Release
Similar to RCKT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Rocket Pharmaceuticals share price?
As of Today at 22:57 UTC, shares in Rocket Pharmaceuticals are trading at $7.23. This share price information is delayed by 15 minutes.
How has the Rocket Pharmaceuticals share price performed this year?
Shares in Rocket Pharmaceuticals last closed at $7.23 and the price had moved by -67.29% over the past 365 days. In terms of relative price strength the Rocket Pharmaceuticals share price has underperformed the S&P500 Index by -69.8% over the past year.
What are the analyst and broker recommendations for Rocket Pharmaceuticals?
The overall consensus recommendation for Rocket Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rocket Pharmaceuticals dividend yield?
Rocket Pharmaceuticals does not currently pay a dividend.
Does Rocket Pharmaceuticals pay a dividend?
Rocket Pharmaceuticals does not currently pay a dividend.
When does Rocket Pharmaceuticals next pay dividends?
Rocket Pharmaceuticals does not currently pay a dividend.
How do I buy Rocket Pharmaceuticals shares?
To buy shares in Rocket Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rocket Pharmaceuticals?
As of the previous close price of $7.23, shares in Rocket Pharmaceuticals had a market capitalisation of $770.93m.
Where are Rocket Pharmaceuticals shares listed?
Here are the trading details for Rocket Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RCKT
What kind of share is Rocket Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Rocket Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rocket Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Rocket Pharmaceuticals is $39.60. That is 447.72% above the last closing price of $7.23.
Analysts covering Rocket Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.37 for the next financial year.
Find out moreWhat is the trend in the Rocket Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rocket Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -55.28%.
As of the last closing price of $7.23, shares in Rocket Pharmaceuticals were trading -49.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rocket Pharmaceuticals PE Ratio?
The Rocket Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.23.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rocket Pharmaceuticals?
Rocket Pharmaceuticals' management team is headed by:
- Roderick Wong - CHM
- Kinnari Patel - PRE
- Gaurav Shah - CEO
- Carlos Garciaparada - CFO
- Isabel Carmona - CHO
- Martin Wilson - SVP
- John Militello - CAO
- Jonathan Schwartz - OTH
- Elisabeth Bjork - IND
- Carsten Boess - IND
- Pedro Granadillo - IND
- Gotham Makker - IND
- David Southwell - IND
- Naveen Yalamanchi - IND